Regulated on activation normal T cell expressed and secreted (RANTES) and eotaxin-2 have been postulated to be responsible for eosinophilia in chronically inflamed nasal mucosa. This study evaluated mucosal production of RANTES and eotaxin-2 in patients with perennial allergic rhinitis (PAR) and nonallergic and allergic form of chronic rhinosinusitis with nasal polyps (CRSwNP) before and after nasal corticosteroid treatment.
Methods:
Twenty patients with PAR, 20 nonallergic and 20 allergic CRSwNP patients, and 20 healthy controls were included. The RANTES and eotaxin-2 levels were measured in nasal secretion samples. The patients with chronic inflammation were treated with fluticasone furoate nasal spray for 2 weeks. Cytological examination and measurement of RANTES and eotaxin-2 in nasal fluid were performed before and after the treatment.
Results:
The levels of RANTES were higher in patients with PAR (P < .05) and nonallergic (P < .01) and allergic CRSwNP patients (P < .001) compared to controls. Eotaxin-2 levels were higher in all 3 inflammation groups compared to healthy subjects (P < .001). After the treatment, we found a significant decrease of RANTES and eotaxin-2 concentrations (P < .001) in all 3 groups of patients.
Conclusion:
The levels of RANTES and eotaxin-2 in nasal fluid could be reliable markers for assessing corticosteroid administration outcomes.
İsmiOÖzcanCKarabacakT. Local effect of neurotrophin-3 in neuronal inflammation of allergic rhinitis: preliminary report. Balkan Med J. 2015;32:364-370.
2.
ShiozawaAMiwaMOnoN. Comparative analysis of cytokine release from epithelial cell cultures of the upper airway. Rhinology. 2015;53:135-141.
3.
PerićAVojvodićDVukomanović-ĐurđevićBBaletićN.Eosinophilic inflammation in allergic rhinitis and nasal polyposis. Arh Hig Rada Toksikol. 2011;62:341-348.
4.
NguyenKHSuzukiHWakasugiT. Expression of epidermal growth factors and a tight junction protein in the nasal mucosa of patients with chronic hypertrophic rhinitis. Allergol Immunopathol (Madr). 2013;41:246-254.
5.
KuleZADeveciHSKuleM. The correlation of clinical measures with the histopathological findings in nasal polyposis. ENT Updates. 2015;5:1-8.
6.
MeyerJEBartelsJGöröghT. The role of RANTES in nasal polyposis. Am J Rhinol. 2005;19:15-20.
7.
ScavuzzoMCRocciVFattoriB. Cytokine secretion in nasal mucus of normal subjects and patients with allergic rhinitis. Biomed Pharmacother. 2003;57:366-371.
8.
PawliczakRLewandowska-PolakAKowalskiML.Pathogenesis of nasal polyps: an update. Curr Allergy Asthma Rep. 2005;5:463-471.
9.
De CorsoEBaroniSBattistaM. Nasal fluid release of eotaxin-3 and eotaxin-2 in persistent sinonasal eosinophilic inflammation. Int Forum Allergy Rhinol. 2014;4:617-624.
10.
VenkatesanNLavignePLavigneFHamidQ.Effects of fluticasone furoate on clinical and immunological outcomes (IL-17) for patients with nasal polyposis naive to steroid treatment. Ann Otol Rhinol Laryngol. 2016;125:213-218.
11.
BousquetJKhaltaevNCruzAA. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in colaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8-160.
12.
PearlmanANConleyDB.Review of current guidlines related to the diagnosis and treatment of rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2008;16:226-230.
13.
FokkensWJLundVJMullolJ. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:1-298.
14.
TsicopoulosAShimbaraAde NadaiP. Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis. J Allergy Clin Immunol. 2004;113:462-469.
15.
LildholdtTRundcrantzHBendeMLarsenK.Glucocorticoid treatment for nasal polyps: the use of topical budesonide powder, intramuscular betamethasone, and surgical treatment. Arch Otolaryngol Head Neck Surg. 1997;123:595-600.
16.
LundVJMackayIS.Staging in rhinosinusitis. Rhinology. 1993;31:183-184.
17.
PerićABaletićNSotirovićJŠpadijer-MirkovićC.Macrophage inflammatory protein—1 production and eosinophil infiltration in chronic rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol. 2015;124:266-272.
18.
KramerMFJordanTRKlemensC. Factors contributing to nasal allergic late phase eosinophilia. Am J Otolaryngol. 2006;27:190-199.
19.
De CorsoEBaroniSLucidiD. Nasal lavage levels of granulocyte-macrophage colony-stimulating factor and chronic nasal hypereosinophilia. Int Forum Allergy Rhinol. 2015;5:557-562.
20.
DereköySKenarFYavaşGF. The influence of iris color and retina pigment epithelium melanin on allergic rhinitis. ENT Updates. 2016;6:23-28.
21.
MarcellaRCroceAMorettiA. Transcription and translation of the chemokines RANTES and MCP-1 in nasal polyps and mucosa in allergic and non-allergic rhinopathies. Immunol Let. 2003;90:71-75.
22.
FundováPFundaDPKovářD. Increased expression of chemokine receptors CCR1 and CCR3 in nasal polyps: molecular basis for recruitment of the granulocyte infiltrate. Folia Microbiol. 2013;58:219-224.
23.
SajiFNonakaMPawankarR.Expression of RANTES by IL-1β and TNF-α stimulated nasal polyp fibroblasts. Auris Nasus Larynx. 2000;27:247-252.
24.
Ritter SansoniESautterNBMaceJC. Vitamin D3 as a novel regulator of basic fibroblast growth factor in chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol. 2015;5:191-196.
25.
RammalATewfikMRousseauS.Differences in RANTES and IL-6 levels among chronic rhinosinusitis patients with predominant gram-negative and gram-positive infection. J Otolaryngol Head Neck Surg. 2017;46:7.
26.
ShinS-HParkJ-YJeonC-H. Quantitative analysis of eotaxin and RANTES messenger RNA in nasal polyps: association of tissue and nasal eosinophilia. Laryngoscope. 2000;110:1353-1357.
27.
LaingKSecombesCJ.Chemokines. Dev Comp Immunol. 2004;28:443-460.
28.
BülbülTGümüştekin BülbülÖCüçlüO. Effect of glucocorticoids on nasal polyposis, with detection of inflammatory response by measurement of nitric oxide levels in nasal polyp tissue. J Laryngol Otol. 2013;127:584-589.
29.
KumarRKumarDParakhA.Fluticasone furoate: a new intranasal corticosteroid. J Postgrad Med. 2012;58:79-83.
30.
PerićAVojvodićDMatković-JožinS.Effect of long-term, low-dose clarithromycin on T helper 2 cytokines, eosinophilic cationic protein and the ‘regulated on activation, normal T cell expressed and secreted’ chemokine in the nasal secretions of patients with nasal polyposis. J Laryngol Otol. 2012;126:495-502.
31.
Van DrunenCMeltzerEOBachertC. Nasal allergies are beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate. Allergy. 2005;60(suppl 80):5-19.
32.
ShahSABergerRLMcDermottJ. Regional deposition of mometasone furoate nasal spray suspension in humans. Allergy Asthma Proc. 2015;36:48-57.
33.
FrieriMTherattilJChavarriaV. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1998;81:431-437.
34.
RoumestanCHenriquetCBousquetJMathieuM.Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. Clin Exp Allergy. 2003;33:895-901.
